Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567228653> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W1567228653 abstract "Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC).251 patients were randomly divided into pemetrexed combined with cisplatin group (PP group) with 127 cases and gemcitabine combined with cisplatin group (GP group) with 124 cases. PP group received pemetrexed 500 mg/m² iv infusion d1 and cisplatin 75 mg/m² iv infusion d1, whereas GP group received gemcitabine 1,000 mg/m² iv infusion d1,8 and cisplatin 75 mg/m² iv infusion d1. The treatment cycle was once every three weeks. In addition, folic acid, vitamin B12, and dexamethasone were administered in both groups.The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively. The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%. The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively. The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively. The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group. The results were statistically significant. However, there were no significant differences in total response rates, tumor progression duration, and median survival rates of 1 and 2 years. The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group. The results were statistically significant.The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC." @default.
- W1567228653 created "2016-06-24" @default.
- W1567228653 creator A5001732325 @default.
- W1567228653 creator A5006794153 @default.
- W1567228653 creator A5012492614 @default.
- W1567228653 creator A5018174872 @default.
- W1567228653 creator A5025910593 @default.
- W1567228653 creator A5040769857 @default.
- W1567228653 creator A5043365458 @default.
- W1567228653 creator A5045176687 @default.
- W1567228653 creator A5046525642 @default.
- W1567228653 creator A5047320009 @default.
- W1567228653 creator A5051363890 @default.
- W1567228653 creator A5056813172 @default.
- W1567228653 creator A5071263487 @default.
- W1567228653 creator A5074092905 @default.
- W1567228653 creator A5075877965 @default.
- W1567228653 creator A5086360069 @default.
- W1567228653 date "2012-10-01" @default.
- W1567228653 modified "2023-09-27" @default.
- W1567228653 title "[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]." @default.
- W1567228653 cites W1533541750 @default.
- W1567228653 cites W1570731453 @default.
- W1567228653 cites W2009246475 @default.
- W1567228653 cites W2040376006 @default.
- W1567228653 cites W209121735 @default.
- W1567228653 cites W2099725888 @default.
- W1567228653 cites W2100780413 @default.
- W1567228653 cites W2106664438 @default.
- W1567228653 cites W2115658330 @default.
- W1567228653 cites W3145077989 @default.
- W1567228653 doi "https://doi.org/10.3779/j.issn.1009-3419.2012.10.02" @default.
- W1567228653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5999833" @default.
- W1567228653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23075680" @default.
- W1567228653 hasPublicationYear "2012" @default.
- W1567228653 type Work @default.
- W1567228653 sameAs 1567228653 @default.
- W1567228653 citedByCount "3" @default.
- W1567228653 countsByYear W15672286532014 @default.
- W1567228653 countsByYear W15672286532015 @default.
- W1567228653 countsByYear W15672286532018 @default.
- W1567228653 crossrefType "journal-article" @default.
- W1567228653 hasAuthorship W1567228653A5001732325 @default.
- W1567228653 hasAuthorship W1567228653A5006794153 @default.
- W1567228653 hasAuthorship W1567228653A5012492614 @default.
- W1567228653 hasAuthorship W1567228653A5018174872 @default.
- W1567228653 hasAuthorship W1567228653A5025910593 @default.
- W1567228653 hasAuthorship W1567228653A5040769857 @default.
- W1567228653 hasAuthorship W1567228653A5043365458 @default.
- W1567228653 hasAuthorship W1567228653A5045176687 @default.
- W1567228653 hasAuthorship W1567228653A5046525642 @default.
- W1567228653 hasAuthorship W1567228653A5047320009 @default.
- W1567228653 hasAuthorship W1567228653A5051363890 @default.
- W1567228653 hasAuthorship W1567228653A5056813172 @default.
- W1567228653 hasAuthorship W1567228653A5071263487 @default.
- W1567228653 hasAuthorship W1567228653A5074092905 @default.
- W1567228653 hasAuthorship W1567228653A5075877965 @default.
- W1567228653 hasAuthorship W1567228653A5086360069 @default.
- W1567228653 hasConcept C123321153 @default.
- W1567228653 hasConcept C126322002 @default.
- W1567228653 hasConcept C143998085 @default.
- W1567228653 hasConcept C2776256026 @default.
- W1567228653 hasConcept C2776694085 @default.
- W1567228653 hasConcept C2777240266 @default.
- W1567228653 hasConcept C2778239845 @default.
- W1567228653 hasConcept C2780258809 @default.
- W1567228653 hasConcept C2780456651 @default.
- W1567228653 hasConcept C29730261 @default.
- W1567228653 hasConcept C71924100 @default.
- W1567228653 hasConcept C90924648 @default.
- W1567228653 hasConceptScore W1567228653C123321153 @default.
- W1567228653 hasConceptScore W1567228653C126322002 @default.
- W1567228653 hasConceptScore W1567228653C143998085 @default.
- W1567228653 hasConceptScore W1567228653C2776256026 @default.
- W1567228653 hasConceptScore W1567228653C2776694085 @default.
- W1567228653 hasConceptScore W1567228653C2777240266 @default.
- W1567228653 hasConceptScore W1567228653C2778239845 @default.
- W1567228653 hasConceptScore W1567228653C2780258809 @default.
- W1567228653 hasConceptScore W1567228653C2780456651 @default.
- W1567228653 hasConceptScore W1567228653C29730261 @default.
- W1567228653 hasConceptScore W1567228653C71924100 @default.
- W1567228653 hasConceptScore W1567228653C90924648 @default.
- W1567228653 hasLocation W15672286531 @default.
- W1567228653 hasOpenAccess W1567228653 @default.
- W1567228653 hasPrimaryLocation W15672286531 @default.
- W1567228653 isParatext "false" @default.
- W1567228653 isRetracted "false" @default.
- W1567228653 magId "1567228653" @default.
- W1567228653 workType "article" @default.